Indeed, CXCL2 expression has been used to enhance the antitumor immunity of the oncolytic virus in orthotopic syngeneic murine breast cancer models through the enhancement of cytotoxic T lymphocytes [45]. This evidence concerns the gene CXCL2 and breast carcinoma.